Top Page
Cynata Therapeutics Limited
(OTC:CYP)
Cynata Therapeutics Limited (CYP) vs. S&P 500 (SPY)
Cynata Therapeutics Limited Business Overview & Revenue Model
Cynata Therapeutics Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.74M | 2.32M | 1.65M | 7.77M | 1.55M | 7.01M | Gross Profit |
| 1.60M | 2.32M | 1.37M | 7.49M | 1.27M | 6.73M | EBIT |
| -15.67M | -8.81M | -16.54M | -6.90M | -9.08M | -10.51M | EBITDA |
| -9.06M | -9.95M | -15.65M | -6.00M | -8.80M | -5.87M | Net Income Common Stockholders |
| -8.85M | -9.74M | -14.28M | -5.45M | -7.69M | -3.64M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 10.51M | 6.21M | 16.17M | 23.80M | 26.72M | 13.65M | Total Assets |
| 12.86M | 8.39M | 18.99M | 26.55M | 29.97M | 17.48M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -10.51M | -6.21M | -16.17M | -23.80M | -26.72M | -13.65M | Total Liabilities |
| 1.37M | 1.17M | 2.26M | 2.59M | 1.60M | 689.74K | Stockholders Equity |
| 11.49M | 7.22M | 16.73M | 23.96M | 28.37M | 16.79M |
| Cash Flow | Free Cash Flow | ||||
| -8.08M | -9.96M | -14.28M | -3.30M | -5.16M | -3.39M | Operating Cash Flow |
| -8.03M | -9.96M | -14.28M | -3.30M | -5.16M | -3.39M | Investing Cash Flow |
| -50.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 7.49M | 0.00 | 6.72M | 210.12K | 18.20M | 10.06M |
Cynata Therapeutics Limited Technical Analysis
Cynata Therapeutics Limited Peers Comparison
Cynata Therapeutics Limited Corporate Events
Cynata Therapeutics announced an investor webinar hosted by CEO Dr. Kilian Kelly, highlighting ongoing clinical trials and advancements in their Cymerus™ platform. The company’s focus on developing next-generation cellular therapies positions it strongly within the biotechnology industry, with ongoing trials in GvHD, kidney transplantation, and osteoarthritis, and preclinical success in various other diseases, indicating potential future growth and impact on stakeholders.
Cynata Therapeutics Limited has reported significant progress in its clinical trials, with a Phase 2 trial for acute graft-versus-host disease nearing 60% recruitment and results expected by late 2025. The company also anticipates results from its Phase 3 osteoarthritis trial in the first half of 2026. Additionally, Cynata’s Phase 1 trial in kidney transplantation continues with the first cohort expected to complete in Q2 2025. These developments highlight Cynata’s strategic focus on advancing its pipeline and strengthening its position in the biotechnology industry, with a strong cash balance supporting operations into mid-2026.
The Australian Federal Government has announced funding for the Solutions for Manufacturing Advanced Regenerative Therapies Cooperative Research Centre (SMART CRC), with Cynata Therapeutics set to play a key role as a Core Partner. This initiative aims to create a collaborative ecosystem for regenerative therapy manufacturing in Australia, with a budget of $238 million and over 60 partners. The involvement in SMART CRC presents Cynata with opportunities to advance its research and development projects, potentially enhancing its position in the regenerative medicine industry.
Cynata Therapeutics Limited has established a new Scientific Advisory Board (SAB) composed of globally recognized experts in cell-based therapies. This board aims to provide strategic scientific guidance and oversight for the company’s research and development efforts. The SAB includes Professor John Rasko as Chair, Professor Igor Slukvin, and Dr. Derek Hei, all of whom have significant experience and contributions to the field. This move is expected to help Cynata maintain its leading position in iPSC-based therapeutic development, potentially impacting its operations and industry standing positively.
Cynata Therapeutics announced promising results from preclinical studies of its Cymerus™ MSCs in treating ischaemic heart disease, the leading global cause of death. The studies revealed that encapsulated Cymerus™ MSCs significantly improved heart function and reduced harmful structural changes in heart tissues in a rat model of heart attack. This novel, minimally invasive delivery method may enhance clinical translation and long-term effects, potentially addressing a critical unmet need in post-heart attack care. The research, supported by a $1 million Australian Government grant, was conducted in collaboration with multiple institutions and has been submitted for peer review.
Cynata Therapeutics Limited has announced a change in the director’s interest notice, specifically regarding Dr. Geoffrey Brooke. The change involved the expiry of 69,767 listed options exercisable at $0.30, which expired on April 1, 2025. This adjustment reflects a routine update in the director’s securities holdings, with implications for the company’s governance and transparency practices.
Cynata Therapeutics Limited is participating in the Advanced Therapies Congress 2025, Europe’s largest cell and gene therapy conference, held in London. Dr. Mathias Kroll, Cynata’s Chief Business Officer, will present the company’s clinical development programs and engage in partnering meetings, highlighting the company’s strategic engagement in the global biotechnology landscape. This participation underscores Cynata’s commitment to advancing its stem cell therapies and strengthening its industry position, potentially impacting stakeholders by showcasing its innovative Cymerus™ technology and ongoing clinical trials.
Cynata Therapeutics announced its participation in the 2025 Euroz Hartleys Institutional Investor Conference, where CEO Dr. Kilian Kelly will present and engage with institutional investors. This participation highlights Cynata’s ongoing efforts to engage stakeholders and showcase its advancements in cell therapeutics, potentially enhancing its industry positioning and investor relations.
Cynata Therapeutics Limited reported a decrease in revenue and other income by 22.61% for the half-year ending December 31, 2024, compared to the previous year. Despite this, the company reduced its comprehensive loss by 19.63%, indicating improved financial management. No dividends were declared, and the net tangible asset backing per ordinary security also decreased. The financial results reflect ongoing challenges but also highlight efforts to mitigate losses, which could impact stakeholder confidence and market positioning.
Cynata Therapeutics Limited announced the expiration of its 18,104,720 listed CYPOA options, which will lapse if not exercised by April 1, 2025. Each option allows the holder to purchase one ordinary share at $0.30, and the expiration could impact the company’s capital structure and investor decisions, as the current share price is below the exercise price.
Cynata Therapeutics Limited has reported a change in the interests of its director, Dr. Paul K Wotton, in the company’s securities. This change involves the conversion of 69,767 listed options into ordinary shares. The move signifies a potential realignment of interests or strategic decision by the director, which may have implications for his engagement with the company and could reflect his confidence in its future prospects.
Cynata Therapeutics Limited has announced the issuance of 69,767 ordinary fully paid securities on February 20, 2025, under the ASX code CYP. This move could potentially enhance the company’s financial flexibility and strengthen its market presence, benefiting stakeholders by supporting ongoing and future projects.
Cynata Therapeutics Limited will host an investor webinar led by CEO Dr. Kilian Kelly to engage with shareholders. The company’s ongoing clinical trials include a Phase 2 trial of CYP-001 for GvHD, a Phase 1/2 trial for kidney transplant patients, and a Phase 3 trial for osteoarthritis, highlighting their commitment to advancing their cell therapeutics pipeline.